Bufexamac-containing medicines to be banned

Published: 2010-12-10 06:56:00

Updated: 2010-12-10 06:56:00

The Korea Food and Drug Administration (KFDA) said on December 8 it has decided to ban sales of controversial bufexamac-based drugs, because of high risk of contact allergies.

Bufexamac is a non-steroidal anti-inflammatory drug (NSAID), used as topical formulations to treat dermatological dise...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK